For a leader in drug delivery technology struggling with how to differentiate its early-phase assets and how to prioritise its investments, I developed new insights from bringing together disparate data sources already available within the company, together with market forecasts and assessments of the likelihood of success in the next phases. This was used to develop a full probabilistic understanding of the value and resource requirements of each asset and to make recommendations about where to focus investment.